Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, withdrew its plans for an initial public offering on Friday. It originally filed in January 2025 with a proposed deal size of $100 million.
Its top shareholder, Alcon, bought a majority share in the company in March 2025, after previously attempting to sue to stop Aurion Biotech from pursuing an IPO.
The Seattle, WA-based company was founded in 2016 and planned to list on the NYSE under the symbol AURN. J.P. Morgan, BofA Securities, Piper Sandler, and Wells Fargo Securities were set to be the joint bookrunners on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.